Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors - Trial NCT00127049
Access comprehensive clinical trial information for NCT00127049 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gustave Roussy, Cancer Campus, Grand Paris and is currently status unknown. The study focuses on Germ Cell Tumor. Target enrollment is 37 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gustave Roussy, Cancer Campus, Grand Paris
Timeline & Enrollment
Phase 2
Dec 01, 2004
N/A
Primary Outcome
Complete response rate
Summary
This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide
 (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted
 favorable prognosis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00127049
Non-Device Trial